A Phase 1 Study of KITE-753 in Relapsed/Refractory B-Cell ALL

Not Yet Recruiting Phase 1 NCT07674823

Study Description

A clinical study testing the safety and recommended dose of a CAR-T cell therapy called KITE-753 in patients whose B-cell acute lymphoblastic leukemia (ALL) has come back or has not responded to prior treatment

Study Details

Registry ID:
NCT07674823
Conditions:
B-cell Acute Lymphoblastic Leukemia
Phase:
Phase 1
Target Enrollment:
18 participants
Start Date:
Age Range:
18–999 years
Healthy Volunteers:
No

Study Locations (1 site)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →